Thanks for filling in details and possibilities. There should / has to be a 'fit' for RLF in this. DrJJ spent a lot of time on RLF during the presentation. There is still a 50%+ chance the FDA may say continue the Trial and present full data. I like the scenarios in the previous post and I have said, buyout or ? Taking care of our OS into a new entity...